BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN
BEGIN:VTIMEZONE
TZID:Eastern Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Eastern Standard Time
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Eastern Daylight Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Adolphus Hotel Registration:&nbsp\;www.regonline.com/DallasAMR 
  \nAntibody mediated rejection is a well-known and feared entity in all so
 lid organ transplants &ndash\; except the liver. Previous studies and lite
 rature regarding liver allografts have been inconsistent\, and mounting ev
 idence has shown the pathologic potential of DSA in liver and SLKT recipie
 nts. The goal of this ground-breaking conference is to bring about a meeti
 ng of the minds to define AMR in liver transplantation and forge a path fo
 r future research in this burgeoning area of research. The conference feat
 ures an esteemed panel of experts in their fields\, and is designed specif
 ically for Transplant Surgeons\, Transplant Pathologists\, Transplant Hepa
 tologists\, Transplant Nephrologists\, and HLA Laboratory PhDs.&nbsp\;Plea
 se see this paper highlighting the importance of Donor Specific Antibodies
  (DSA) in simultaneous liver kidney transplant patients.
DTEND:20130323T050000Z
DTSTAMP:20260415T193239Z
DTSTART:20130322T050000Z
LOCATION:Texas\,Dallas
SEQUENCE:0
SUMMARY:Antibody Mediated Rejection in Liver Transplantation
UID:RFCALITEM639118639591856316
X-ALT-DESC;FMTTYPE=text/html:<p><strong>Adolphus Hotel</strong></p> <p><str
 ong>Registration</strong>:&nbsp\;<a href="http://www.regonline.com/DallasA
 MR">www.regonline.com/DallasAMR</a> <br /> <br />\nAntibody mediated rejec
 tion is a well-known and feared entity in all solid organ transplants &nda
 sh\; except the liver. Previous studies and literature regarding liver all
 ografts have been inconsistent\, and mounting evidence has shown the patho
 logic potential of DSA in liver and SLKT recipients. The goal of this grou
 nd-breaking conference is to bring about a meeting of the minds to define 
 AMR in liver transplantation and forge a path for future research in this 
 burgeoning area of research. The conference features an esteemed panel of 
 experts in their fields\, and is designed specifically for Transplant Surg
 eons\, Transplant Pathologists\, Transplant Hepatologists\, Transplant Nep
 hrologists\, and HLA Laboratory PhDs.&nbsp\;<a href="http://www.camenaegro
 up.com/ckfinder/userfiles/files/OLearyEtAl-ClassIIAlloantibodyMortalityLiv
 erKidneyTransplantation2013.pdf">Please see this paper highlighting the im
 portance of Donor Specific Antibodies (DSA) in simultaneous liver kidney t
 ransplant patients</a>.</p>
END:VEVENT
END:VCALENDAR